By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson reported after the close of the market Tuesday that its second-quarter revenues swelled 7 percent overall, driven in part by a 9 percent increase in its BD Diagnostics business year over year.

BD had total revenues of $1.92 billion for the three-month period ended March 31, compared to $1.8 billion for the second quarter of 2010. Analysts had expected the company to earn revenues of $1.86 billion for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.